{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-12400"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-12400","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"Formulation and characterization of albumin nanoparticles for NSCLC photochemotherapy","abstract":"Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and is a leading cause of worldwide cancer-related death, which is a strong motivation to develop more efficacious approaches to its treatment. This thesis outlines the construction of folate-targeted bovine serum albumin (FA-BSA) nanoparticles co-loading Chlorin e6 (Ce6), a photodynamic therapy photosensitizer, and Evofosfamide (EVO), a hypoxia-activated prodrug, to enable synergistic photochemotherapy. The 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a water-soluble carbodiimide coupling reagent and used for amide bonds between carboxylic acid and amines. FA-BSA nanoparticles were prepared through a desolvation approach and stabilized through crosslinking by the carbodiimide reagent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form spherical particles of narrow size distribution confirmed through dynamic light scattering and transmission electron microscopy. Encapsulation efficiency studies confirmed high drug load of both Ce6 and EVO, giving credence to albumin as a biocompatible carrier molecule. Release studies in vitro indicated sustained and controlled drug release of light-activation-enhanced Ce6-induced reactive oxygen species production and EVO release triggered by light activation that ablated hypoxic tumor environments. Dual-action methodology improved therapeutic potential through folate receptor-mediated endocytic capture of FA-BSA nanoparticles to exploit selective tumor targeting while simultaneously evading tumor resistance and microenvironment obstacles. These results collectively substantiate that FA-BSA tumor-targeting nanocarriers can improve tumor selectivity, enhance retention time, and elevate therapeutic effectiveness while reducing systemic toxicity. This work lays a strong groundwork to explore through translational studies multifunction nanomedicine's translational potential in treating NSCLC.","abstract_html":"Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and is a leading cause of worldwide cancer-related death, which is a strong motivation to develop more efficacious approaches to its treatment. This thesis outlines the construction of folate-targeted bovine serum albumin (FA-BSA) nanoparticles co-loading Chlorin e6 (Ce6), a photodynamic therapy photosensitizer, and Evofosfamide (EVO), a hypoxia-activated prodrug, to enable synergistic photochemotherapy. The 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a water-soluble carbodiimide coupling reagent and used for amide bonds between carboxylic acid and amines. FA-BSA nanoparticles were prepared through a desolvation approach and stabilized through crosslinking by the carbodiimide reagent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form spherical particles of narrow size distribution confirmed through dynamic light scattering and transmission electron microscopy. Encapsulation efficiency studies confirmed high drug load of both Ce6 and EVO, giving credence to albumin as a biocompatible carrier molecule. Release studies in vitro indicated sustained and controlled drug release of light-activation-enhanced Ce6-induced reactive oxygen species production and EVO release triggered by light activation that ablated hypoxic tumor environments. Dual-action methodology improved therapeutic potential through folate receptor-mediated endocytic capture of FA-BSA nanoparticles to exploit selective tumor targeting while simultaneously evading tumor resistance and microenvironment obstacles. These results collectively substantiate that FA-BSA tumor-targeting nanocarriers can improve tumor selectivity, enhance retention time, and elevate therapeutic effectiveness while reducing systemic toxicity. This work lays a strong groundwork to explore through translational studies multifunction nanomedicine&#x27;s translational potential in treating NSCLC.","abstract_has_math":false,"creators":["Khan, Faisal Mohammad Shamim"],"institution":"University of South Florida","degree_name":"Master of Science (M.S.)","degree_level":"Thesis","degree_discipline":"Pharmacy","degree_department":null,"school":null,"contributors":["Diane Allen-Gipson, Ph.D.","Qingyu Stephanie Zhou, Ph.D.","Ashwin Parthasarathy, Ph.D.","Vijaykumar Sutariya, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-10-21T07:00:00Z","date_published":"2025-10-21T07:00:00Z","updated_at":"2026-11-19T08:49:32Z","subjects":["Non-small Cell Lung Cancer","Photodynamic Therapy","Folate-Targeted Nanoparticle","Hypoxia","Reactive Oxygen Species","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/11097","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/11097","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-12400","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Diane Allen-Gipson, Ph.D.","Qingyu Stephanie Zhou, Ph.D.","Ashwin Parthasarathy, Ph.D.","Vijaykumar Sutariya, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Khan, Faisal Mohammad Shamim"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-10-21T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis","M.S."]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (M.S.)"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Non-small Cell Lung Cancer","Photodynamic Therapy","Folate-Targeted Nanoparticle","Hypoxia","Reactive Oxygen Species","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/11097"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and is a leading cause of worldwide cancer-related death, which is a strong motivation to develop more efficacious approaches to its treatment. This thesis outlines the construction of folate-targeted bovine serum albumin (FA-BSA) nanoparticles co-loading Chlorin e6 (Ce6), a photodynamic therapy photosensitizer, and Evofosfamide (EVO), a hypoxia-activated prodrug, to enable synergistic photochemotherapy. The 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a water-soluble carbodiimide coupling reagent and used for amide bonds between carboxylic acid and amines. FA-BSA nanoparticles were prepared through a desolvation approach and stabilized through crosslinking by the carbodiimide reagent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form spherical particles of narrow size distribution confirmed through dynamic light scattering and transmission electron microscopy. Encapsulation efficiency studies confirmed high drug load of both Ce6 and EVO, giving credence to albumin as a biocompatible carrier molecule. Release studies in vitro indicated sustained and controlled drug release of light-activation-enhanced Ce6-induced reactive oxygen species production and EVO release triggered by light activation that ablated hypoxic tumor environments. Dual-action methodology improved therapeutic potential through folate receptor-mediated endocytic capture of FA-BSA nanoparticles to exploit selective tumor targeting while simultaneously evading tumor resistance and microenvironment obstacles. These results collectively substantiate that FA-BSA tumor-targeting nanocarriers can improve tumor selectivity, enhance retention time, and elevate therapeutic effectiveness while reducing systemic toxicity. This work lays a strong groundwork to explore through translational studies multifunction nanomedicine's translational potential in treating NSCLC."]},{"key":"dc:title","label":"Title","values":["Formulation and characterization of albumin nanoparticles for NSCLC photochemotherapy"]}]}],"canonical_facts":{"dc:contributor":["Diane Allen-Gipson, Ph.D.","Qingyu Stephanie Zhou, Ph.D.","Ashwin Parthasarathy, Ph.D.","Vijaykumar Sutariya, Ph.D."],"dc:creator":["Khan, Faisal Mohammad Shamim"],"dc:date":["2025-10-21T07:00:00Z"],"dc:description":["Non-small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and is a leading cause of worldwide cancer-related death, which is a strong motivation to develop more efficacious approaches to its treatment. This thesis outlines the construction of folate-targeted bovine serum albumin (FA-BSA) nanoparticles co-loading Chlorin e6 (Ce6), a photodynamic therapy photosensitizer, and Evofosfamide (EVO), a hypoxia-activated prodrug, to enable synergistic photochemotherapy. The 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a water-soluble carbodiimide coupling reagent and used for amide bonds between carboxylic acid and amines. FA-BSA nanoparticles were prepared through a desolvation approach and stabilized through crosslinking by the carbodiimide reagent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) to form spherical particles of narrow size distribution confirmed through dynamic light scattering and transmission electron microscopy. Encapsulation efficiency studies confirmed high drug load of both Ce6 and EVO, giving credence to albumin as a biocompatible carrier molecule. Release studies in vitro indicated sustained and controlled drug release of light-activation-enhanced Ce6-induced reactive oxygen species production and EVO release triggered by light activation that ablated hypoxic tumor environments. Dual-action methodology improved therapeutic potential through folate receptor-mediated endocytic capture of FA-BSA nanoparticles to exploit selective tumor targeting while simultaneously evading tumor resistance and microenvironment obstacles. These results collectively substantiate that FA-BSA tumor-targeting nanocarriers can improve tumor selectivity, enhance retention time, and elevate therapeutic effectiveness while reducing systemic toxicity. This work lays a strong groundwork to explore through translational studies multifunction nanomedicine's translational potential in treating NSCLC."],"dc:identifier":["https://digitalcommons.usf.edu/etd/11097"],"dc:subject":["Non-small Cell Lung Cancer","Photodynamic Therapy","Folate-Targeted Nanoparticle","Hypoxia","Reactive Oxygen Species","Medicinal Chemistry and Pharmaceutics","Nanoscience and Nanotechnology"],"dc:title":["Formulation and characterization of albumin nanoparticles for NSCLC photochemotherapy"],"thesis:degree_discipline":["Pharmacy"],"thesis:degree_level":["Thesis","M.S."],"thesis:degree_name":["Master of Science (M.S.)"],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:49:32Z"}